secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001104659-22-117891
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome reports Q3 net loss of $8.5M; cash $27.1M; COVID antibody trial on track
--------------------------------------------------------------------------------

- Net loss for Q3 2022 was $8.5 million; no revenue from product sales.
- R&D expenses $5.2M, G&A $3.3M; cash and equivalents $27.1M as of Sept 30.
- IMM-BCP-01 Phase 1b enrollment expected by end of 2022; topline data early 2023.
- Oncology pipeline advancing; IND for IMM-ONC-01 planned by mid-2023.
- Preclinical data on anti-EPN1 antibody IMM20059 at SITC showed combo effect with atezolizumab.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465922117891/0001104659-22-117891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465922117891/tm2230173d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-117891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer